John Libbey Eurotext

Hépato-Gastro & Oncologie Digestive

MENU

Adjuvant therapy for colon cancer: what lies ahead after the MOSAIC trial? Volume 17, special issue 5, Cancer colorectal : acquis thérapeutiques récents

Author
Hôpital européen Georges-Pompidou faculté Paris-V, service d’hépatogastroentérologie et d’oncologie digestive 20, rue Leblanc 75015 Paris France

Colon cancer killed more than 16,000 people in 2007 in France. Adjuvant therapy reduces metastatic recurrence, thereby saving several thousand lives every year. Five years ago, the MOSAIC trial established combination therapy with 5-fluorouracil, folinic acid and oxaliplatin as the reference treatment after surgical resection for stage III colon cancers. Since then, there have been very few significant advances. In this review of the latest data on the subject, we will focus on four avenues for future research: is further optimization of chemotherapy possible? Where do targeted therapies fit in an adjuvant setting? Is it possible to modulate chemotherapy in order to enhance its efficacy and tolerance? And finally, is the time of personalized medicine about to come?